Compare Hormel Foods Corp (HRL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Novartis AG — how do they compare? Hormel Foods Corp trades at $19.26 (market cap $10.69B), while Novartis AG trades at $142.94 (market cap $268.57B). The key difference: Novartis AG is far larger — about 25.1× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Novartis AG for 82 Days on average.
| HRL | NVS | |
|---|---|---|
Market Cap | $10.69B | $268.57B |
Volume | 10,041,387 | 1,532,573 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $168.62 |
52-Week Low | $19.42 | $121.80 |
Typical Hold Time | 99 Days | 82 Days |
Enterprise Value | $12.67B | $309.89B |
Dividend Yield | 6.02% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.55, down 1.66% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, while recent quarterly earnings have consistently beaten expectations. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, though cash flow trends show volatility with 2025 net cash flow negative $71M.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 24% upside. Key risks include declining profit margins, high payout ratios, and integration challenges from recent acquisition. The 60-year dividend streak provides stability but raises sustainability concerns amid shrinking raises.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
